Pediatric Vaccines Market By Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit, Recombinant, & Conjugate Vaccines, mRNA Vaccines), By Disease Target (Measles, Hepatitis B, Polio, Rotavirus, Pneumococcal Disease), By Administration Route (Intramuscular, Subcutaneous, Oral), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Pediatric Vaccines Market was valued at USD 38.5 billion in 2024-e and will surpass USD 59.9 billion by 2030; growing at a CAGR of 7.6% during 2025 - 2030.

The pediatric vaccines market is experiencing strong growth due to increased awareness of the importance of immunization in preventing childhood diseases. Vaccines are essential in protecting children from potentially life-threatening diseases, and the expansion of vaccine coverage globally has significantly contributed to the reduction of vaccine-preventable diseases. The market is also fueled by advancements in vaccine technology, such as the development of mRNA vaccines and more effective and safer formulations for younger children.

Increasing government immunization programs, rising healthcare expenditures, and a growing focus on public health in both developed and emerging economies are driving the pediatric vaccines market. Additionally, as the global pediatric population expands and new vaccines targeting emerging diseases are developed, the market is poised for continued growth. The COVID-19 pandemic has also heightened the focus on vaccination, particularly for vulnerable populations such as children, leading to increased investments and research in pediatric vaccines.

Inactivated Vaccines Segment is Largest Owing to Their Safety Profile and Efficacy

The inactivated vaccines segment is the largest in the pediatric vaccines market, primarily due to their safety profile and proven efficacy. Inactivated vaccines are created by killing the virus or bacteria, rendering them unable to cause disease while still stimulating an immune response. This makes them particularly suitable for use in children, who may be more susceptible to the side effects of live vaccines.

Inactivated vaccines are widely used for diseases such as polio, hepatitis A, and influenza. Their extensive use in routine immunization schedules, coupled with the increasing demand for vaccines that can be administered safely and effectively to children, has cemented their dominance in the market. These vaccines are commonly administered as part of combination vaccines, which help streamline the immunization process by reducing the number of injections required.

Intramuscular Route of Administration is Largest Owing to Proven Effectiveness and Ease of Delivery

The intramuscular route of administration is the most commonly used method for pediatric vaccines, as it ensures effective absorption and a robust immune response. Intramuscular injections are generally preferred for vaccines like those against hepatitis B, polio, and measles, as they are absorbed directly into the bloodstream, allowing for a quicker immune response.

This route is favored for its ability to deliver vaccines in a manner that minimizes the risk of local reactions and maximizes the systemic immune response. Moreover, the availability of trained healthcare professionals and the established healthcare infrastructure in many countries further supports the widespread use of intramuscular injections for pediatric immunization.

Subunit, Recombinant, & Conjugate Vaccines Segment is Fastest Growing Owing to Advanced Technology and Disease Control

The subunit, recombinant, and conjugate vaccines segment is the fastest-growing in the pediatric vaccines market, driven by advancements in vaccine technology and a growing understanding of how to target specific pathogens. These vaccines, which contain only specific pieces of the pathogen (such as proteins or sugars), are highly targeted and have fewer side effects compared to whole virus or bacterial vaccines.

Subunit and recombinant vaccines have been instrumental in the development of vaccines against diseases like human papillomavirus (HPV) and pneumococcal disease. The conjugate vaccines, which link a piece of the pathogen to a carrier protein, have significantly improved vaccine efficacy in young children. This segment’s growth is expected to continue as more vaccines are developed to protect against a wider range of infections, providing better long-term disease control and improving vaccination outcomes.

Asia-Pacific is Fastest Growing Region Owing to Expanding Immunization Programs and Increasing Healthcare Access

The Asia-Pacific region is the fastest-growing in the pediatric vaccines market, driven by expanding immunization programs and increasing healthcare access across both urban and rural areas. Governments in countries like India, China, and Southeast Asian nations are ramping up efforts to vaccinate children as part of national public health initiatives.

The region is also witnessing rapid economic development, which is leading to improved healthcare infrastructure, better access to vaccines, and higher levels of healthcare expenditure. Moreover, growing concerns about vaccine-preventable diseases and rising healthcare awareness are further boosting the demand for pediatric vaccines. The global push for increased vaccination coverage is particularly significant in this region, which has large, underserved populations that are benefiting from expanded vaccine access.

Competitive Landscape

The pediatric vaccines market is highly competitive, with major pharmaceutical companies leading the way in research, development, and distribution of vaccines. Companies such as GlaxoSmithKline, Merck & Co., Sanofi Pasteur, and Pfizer are at the forefront, offering a wide range of pediatric vaccines for various diseases, including polio, measles, rotavirus, and pneumonia.

The market is also witnessing the emergence of innovative vaccine solutions, such as mRNA vaccines, which are expected to transform the landscape of pediatric immunization. As competition intensifies, companies are focusing on strengthening their product portfolios through partnerships, acquisitions, and research collaborations to develop new vaccines and improve existing ones. Additionally, there is a growing emphasis on expanding vaccine access in emerging markets, where the need for pediatric immunization is critical for disease prevention.

List of Leading Companies:

• GlaxoSmithKline
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi Pasteur
• Johnson & Johnson
• Novartis AG
• AstraZeneca
• Serum Institute of India
• Bharat Biotech
• Mitsubishi Tanabe Pharma
• Sinovac Biotech
• CSL Limited
• AbbVie Inc.
• Zhejiang Hisun Pharmaceutical
• VBI Vaccines

Recent Developments:

• In December 2024, GlaxoSmithKline launched a new combined vaccine for measles, mumps, rubella, and varicella in children.
• In November 2024, Pfizer Inc. received approval for its new pediatric pneumococcal vaccine for infants and young children.
• In October 2024, Sanofi Pasteur introduced a new combination vaccine targeting polio, hepatitis B, and diphtheria for infants.
• In September 2024, Serum Institute of India expanded its production capacity for pediatric vaccines to meet growing global demand.
• In August 2024, Merck & Co. developed a new rotavirus vaccine aimed at reducing hospitalization rates in young children.

Report Scope: